What’s Going On With Novo Nordisk Stock Thursday? – Novo Nordisk (NYSE:NVO)
Oral Semaglutide Shows Superior Glycaemic Control The phase 3a study evaluated oral semaglutide in patients aged 10–17 years…
Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake – Eli Lilly (NYSE:LLY)
Early Prescription Trends Show Slower Start For Lilly Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390…
Eli Lilly Just Launched Its $149 Obesity Pill – Eli Lilly (NYSE:LLY)
Eli Lilly and Co. (NYSE:LLY) on Wednesday announced that Foundayo (orforglipron) is now available to adults with obesity…
Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a…
Novo Nordisk Leans Into Affordability Amid Rising Competition – Novo Nordisk (NYSE:NVO)
Novo Nordisk A/S (NYSE:NVO) announced on Monday that Wegovy (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic are…
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets – Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)
The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative…